Business Description
Praxis Precision Medicines Inc
NAICS : 541714
SIC : 2834
ISIN : US74006W2070
Share Class Description:
PRAX: Ordinary SharesTotal Employee Number:
10,998Description
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 548.34 | |||||
Equity-to-Asset | 0.97 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 40.8 | |||||
3-Year EPS without NRI Growth Rate | 42.2 | |||||
3-Year FCF Growth Rate | 43.2 | |||||
3-Year Book Growth Rate | 14.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50.5 | |||||
9-Day RSI | 55.14 | |||||
14-Day RSI | 54.48 | |||||
3-1 Month Momentum % | -23.88 | |||||
6-1 Month Momentum % | -16.57 | |||||
12-1 Month Momentum % | 378.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 15.88 | |||||
Quick Ratio | 15.88 | |||||
Cash Ratio | 15.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -97.1 | |||||
Shareholder Yield % | -13.52 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -46.98 | |||||
ROA % | -43.82 | |||||
ROIC % | -124.3 | |||||
3-Year ROIIC % | -33.21 | |||||
ROC (Joel Greenblatt) % | -41763.67 | |||||
ROCE % | -51.41 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 6.42 | |||||
Price-to-Tangible-Book | 6.4 | |||||
EV-to-EBIT | -23.16 | |||||
EV-to-EBITDA | -23.17 | |||||
EV-to-Forward-Revenue | 1718.95 | |||||
EV-to-FCF | -29.32 | |||||
Price-to-GF-Value | 11.92 | |||||
| Price-to-Net-Current-Asset-Value | 12.07 | |||||
| Price-to-Net-Cash | 12.25 | |||||
Earnings Yield (Greenblatt) % | -4.32 | |||||
FCF Yield % | -3.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PRAX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Praxis Precision Medicines Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -13.37 | ||
| Beta | 0.997 | ||
| 3-Year Sharpe Ratio | 1 | ||
| 3-Year Sortino Ratio | 4.27 | ||
| Volatility % | 273.37 | ||
| 14-Day RSI | 54.48 | ||
| 14-Day ATR ($) | 21.317823 | ||
| 20-Day SMA ($) | 305.643 | ||
| 12-1 Month Momentum % | 378.45 | ||
| 52-Week Range ($) | 37.19 - 366.52 | ||
| Shares Outstanding (Mil) | 27.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Praxis Precision Medicines Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Praxis Precision Medicines Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 08:00 | In 118 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 08:30 | In 25 days | ||
| Second quarter earnings results for 2026 | 2026-08-04 | In 24 days | ||
| General meeting for 2026 | 2026-06-10 09:00 | 250.33 (-3.01%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 08:00 | 254.00 (-5.70%) | ||
| Bank of America Securities Health Care Conference | 2026-05-12 19:20 | 331.81 (-0.52%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 338.07 (+0.85%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 337.61 (+4.71%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 11:50 | 336.75 (+0.54%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-19 08:00 | 328.93 (-0.10%) |
Show
Entries
Praxis Precision Medicines Inc Frequently Asked Questions
What is Praxis Precision Medicines Inc(PRAX)'s stock price today?
The current price of PRAX is $323.81. The 52 week high of PRAX is $366.52 and 52 week low is $37.19.
When is next earnings date of Praxis Precision Medicines Inc(PRAX)?
The next earnings date of Praxis Precision Medicines Inc(PRAX) is 2026-08-04 Est..
Does Praxis Precision Medicines Inc(PRAX) pay dividends? If so, how much?
Praxis Precision Medicines Inc(PRAX) does not pay dividend.
Guru Commentaries on NAS:PRAX
No articles.
Press Release
Articles on Praxis Precision Medicines Inc
Headlines
See More- 1
Jun 29, 2026
Praxis sees encephalopathies asset relutrigine action date extended
Seeking Alpha • 5:14pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers